It will be of interest to monitor the tumor cell-directed approach (HER2) as opposed to the myeloid-directed approaches (CCR2 and salmonella) to gain greater insight into the cell type of relevance for therapeutic STING targeting. The gene discussed is ERBB2; the disease is neoplasm.